Stempoint Capital LP Sells 150,806 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Stempoint Capital LP lowered its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 43.0% in the first quarter, Holdings Channel.com reports. The fund owned 200,267 shares of the company’s stock after selling 150,806 shares during the quarter. Structure Therapeutics comprises 1.8% of Stempoint Capital LP’s portfolio, making the stock its 16th biggest holding. Stempoint Capital LP’s holdings in Structure Therapeutics were worth $9,653,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Sterling Capital Management LLC purchased a new stake in Structure Therapeutics in the first quarter worth $28,000. State of Wyoming bought a new stake in shares of Structure Therapeutics during the second quarter worth $28,000. CWM LLC boosted its stake in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the period. Assetmark Inc. boosted its stake in shares of Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after purchasing an additional 449 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Structure Therapeutics in the fourth quarter worth about $127,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Trading Down 1.1%

Shares of GPCR stock opened at $47.35 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $15.80 and a twelve month high of $94.90. The stock has a market capitalization of $3.37 billion, a price-to-earnings ratio of -54.42 and a beta of -1.50. The stock has a fifty day simple moving average of $46.12 and a two-hundred day simple moving average of $55.43.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. Research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on GPCR shares. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Canaccord Genuity Group started coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reduced their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.55.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.